Jie-Syuan Wu

Ms. Jie-Syuan Wu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

11 October 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LLLee‐Yuan Lin
Lee‐Yuan Lin
JWJie-Syuan Wu
Jie-Syuan Wu
WJWei‐Jung Jeng
Wei‐Jung Jeng
CTChen‐Hsin Tsai
Chen‐Hsin Tsai
JSJia‐Wei Sun
Jia‐Wei Sun
SLShyh-Hsiang Lin
Shyh-Hsiang Lin

24 February 2025 in Life
Verified
Journal Article
Open access
PDF file
GHGee-Sern Jison Hsu
Gee-Sern Jison Hsu
JWJie-Syuan Wu
Jie-Syuan Wu
YHYin-Kai Dean Huang
Yin-Kai Dean Huang
CCChun-Chieh Chiu
Chun-Chieh Chiu
Jiunn Horng KangJiunn Horng Kang
Jiunn Horng Kang
Background: Occupational low back pain (LBP) is a pervasive health issue that significantly impacts productivity and contributes to work-related musculoskeletal disorders (WMSDs). Inadequate lifting postures are a primary, modifiable risk factor associated with LBP, making early detection of unsafe practices crucial to mitigating occupational injuries. Our study aims to address these limitations by developing a markerless, smartphone-based camera system integrated with a deep learning model capable of accurately classifying lifting postures. Material and Method: We recruited 50 healthy adults who participated in lifting tasks using correct and incorrect postures to build a robust dataset. Participants lifted boxes of varying sizes and weights while their movements were recorded from multiple angles and heights to ensure comprehensive data capture. We used the OpenPose algorithm to detect and extract key body points to calculate relevant biomechanical features. These extracted features served as inputs to a bidirectional long short-term memory (LSTM) model, which classified lifting postures into correct and incorrect categories. Results: Our model demonstrated high classification accuracy across all datasets, with accuracy rates of 96.9% for Tr, 95.6% for the testing set, and 94.4% for training. We observed that environmental factors, such as camera angle and height, slightly influenced the model’s accuracy, particularly in scenarios where the subject’s posture partially occluded key body points. Nonetheless, these variations were minor, confirming the robustness of our system across different conditions. Conclusions: This study demonstrates the feasibility and effectiveness of a smartphone camera and AI-based system for lifting posture classification. The system’s high accuracy, low setup cost, and ease of deployment make it a promising tool for enhancing workplace ergonomics. This approach highlights the potential of artificial intelligence to improve occupational safety and underscores the relevance of affordable, scalable solutions in the pursuit of healthier workplaces.

18 March 2026 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
LLLee‐Yuan Lin
Lee‐Yuan Lin
CHCheng‐Hao Hsu
Cheng‐Hao Hsu
HSHung Su
Hung Su
JSJia‐Wei Sun
Jia‐Wei Sun
JWJie-Syuan Wu
Jie-Syuan Wu
SLShyh-Hsiang Lin
Shyh-Hsiang Lin
Background: Repeated low‐level red‐light (RLRL) therapy is a novel, non‐invasive intervention for controlling paediatric myopia progression. Despite increasing clinical use, questions remain regarding the magnitude, durability, and safety of treatment effects. This study evaluated its efficacy and safety based on randomised controlled trial (RCT) evidence. Methods: PubMed, Embase, and the Cochrane Library were searched through August 2025 for RCTs comparing RLRL with control in children (< 18 years). The primary outcome was spherical equivalent refraction (SER); secondary outcomes included axial length (AL), choroidal thickness (ChT), anterior chamber depth (ACD), central corneal thickness (CCT), lens thickness (LT), and uncorrected visual acuity (UCVA). Evidence certainty was assessed using the GRADE framework. Results: Twenty‐eight RCTs (3573 participants) were included. RLRL therapy achieved duration‐dependent myopia control ( p < 0.05), with pooled improvements versus control at 12 months of +0.68 D in SER, −0.30 mm in AL, and +26.7 μm in ChT. Subgroup analysis showed greater efficacy in children with higher baseline myopia ( p < 0.0001), with comparable effects between 5‐ and 7‐day regimens. UCVA was higher with RLRL therapy. ACD, CCT, and LT were unchanged. Reported adverse events were mild and transient, with no consistent structural or functional abnormalities described. Conclusions: RLRL was associated with duration‐dependent reductions in myopia progression up to 1 year. Reported structural parameters remained stable and adverse events were generally mild. Moderate‐certainty evidence supports improvement in SER and ChT, whereas evidence for AL remains of lower certainty. Longer‐term trials incorporating comprehensive retinal safety assessment are required. Trial Registration: PROSPERO CRD420251112677

1 June 2026 in Obesity
Verified
Journal Article
Open access
JWJie-Syuan Wu
Jie-Syuan Wu
LLLee‐Yuan Lin
Lee‐Yuan Lin
JSJia‐Wei Sun
Jia‐Wei Sun
WYWei‐Ting Yu
Wei‐Ting Yu
FYFara Silvia Yuliani
Fara Silvia Yuliani
SLShyh-Hsiang Lin
Shyh-Hsiang Lin
Objective: This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications. Methods: This retrospective cohort study included deidentified TriNetX data on ≥ 50‐year‐old nondiabetic adults with obesity. After 1:1 propensity score matching on demographic, clinical, and laboratory covariates, 18,062 GLP‐1 RA users were compared with non‐GLP‐1 medication users. The primary outcome was incident osteoporosis; secondary outcomes included major osteoporotic fractures, cervical and thoracolumbar disc disorders, and osteoarthritis. Results: GLP‐1 RA use was associated with lower risks of osteoporosis (relative risk [RR] 0.48; 95% CI, 0.43–0.52; number needed to treat [NNT] = 28), major osteoporotic fractures (RR 0.15; 95% CI, 0.11–0.22; NNT = 88), cervical disc degeneration (RR 0.34; 95% CI, 0.28–0.41; NNT = 63), thoracolumbar disc disease (RR 0.36; 95% CI, 0.33–0.40; NNT = 20), and osteoarthritis (RR 0.45; 95% CI, 0.43–0.48; NNT = 9). Protective associations were consistent across age, sex, BMI, and drug subtype subgroups and remained robust in sensitivity analyses. Conclusions: GLP‐1 RA use was associated with favorable musculoskeletal outcomes, including lower risks of osteoporosis and fractures, in nondiabetic adults with obesity compared with other obesity medications.

4 September 2026 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Open access
LLLee‐Yuan Lin
Lee‐Yuan Lin
JWJie-Syuan Wu
Jie-Syuan Wu
WJWei‐Jung Jeng
Wei‐Jung Jeng
CTChen‐Hsin Tsai
Chen‐Hsin Tsai
SLShu‐Yu Liu
Shu‐Yu Liu
SLShyh-Hsiang Lin
Shyh-Hsiang Lin
Background and Purpose: Glaucoma, a neurodegenerative optic neuropathy and leading cause of irreversible vision loss, shares vascular and neurodegenerative mechanisms with dementia. The 2024 Lancet Commission newly identified visual impairment as a modifiable dementia risk factor. As glaucoma management ranges from long‐term medical therapy to laser/surgical intervention, it remains uncertain whether treatment modality influences long‐term systemic outcomes such as dementia. This study compares dementia risk in patients receiving glaucoma surgery versus medical therapy. Methods: Glaucoma patients aged ≥ 40 years and diagnosed and managed before July 2021 were identified in the TriNetX database and followed from the first definitive treatment—surgery or initiation of medical therapy—until dementia diagnosis, death, or July 2026. The primary outcome was all‐cause dementia; secondary outcomes included Alzheimer's disease, vascular dementia, and visual loss. Subgroup analyses examined surgical timing, modality, age, sex, and comorbidities. Results: After 1:1 propensity score matching, 51,923 patients were included in each cohort (mean age 64 years; 55.3% female). Glaucoma surgery was associated with reduced risks of all‐cause dementia (HR 0.81) and vascular dementia (HR 0.53), a non‐significant reduction in Alzheimer's disease (HR 0.87), and a higher risk of visual loss (HR 1.52), consistent with more advanced disease among surgical candidates. Associations were stronger with late surgery, traditional incisional procedures, younger age, and absence of comorbidities. Conclusions: Patients who underwent glaucoma surgery were associated with a lower subsequent risk of all‐cause dementia and vascular dementia, with a non‐significant trend for Alzheimer's disease, compared with those receiving medical therapy. These findings suggest that surgical management is associated with more favourable long‐term cognitive outcomes beyond ocular benefits, which may provide additional context for treatment‐escalation decisions in suitable patients.